Exposure to polycyclic aromatic hydrocarbons (PAHs) and bladder cancer: evaluation from a gene-environment perspective in a hospital-based case-control study in the Canary Islands (Spain)

Abstract

Background:

Exposure to polycyclic aromatic hydrocarbons (PAHs) has been linked to bladder cancer.

Objective:

To evaluate the role of PAHs in bladder cancer, PAHs serum levels were measured in patients and controls from a case-control study.

Methods:

A total of 140 bladder cancer patients and 206 healthy controls were included in the study. Sixteen PAHs were analyzed from the serum of subjects by gas chromatography–mass spectrometry.

Results:

Serum PAHs did not appear to be related to bladder cancer risk, although the profile of contamination by PAHs was different between patients and controls: pyrene (Pyr) was solely detected in controls and chrysene (Chry) was exclusively detected in the cases. Phenanthrene (Phe) serum levels were inversely associated with bladder cancer (OR = 0·79, 95%CI = 0·64–0·99, P = 0·030), although this effect disappeared when the allelic distribution of glutathione-S-transferase polymorphisms of the population was introduced into the model (multinomial logistic regression test, P = 0·933). Smoking (OR = 3·62, 95%CI = 1·93–6·79, P<0·0001) and coffee consumption (OR = 1·73, 95%CI = 1·04–2·86, P = 0·033) were relevant risk factors for bladder cancer.

Conclusions:

Specific PAH mixtures may play a relevant role in bladder cancer, although such effect seems to be highly modulated by polymorphisms in genes encoding xenobiotic-metabolizing enzymes.

Keywords:

• Polycyclic aromatic hydrocarbons
• Bladder cancer
• Risk profession
• Gene-environment interaction

Acknowledgements

This work was supported by FUNCIS PI 35/08 and FUNCIS PI 55/07 of the Gobierno de Canarias (Spain) and by PI 19/08 of the Instituto Canario de Investigación del Cáncer (ICIC).